Limits...
Stereotactic body radiotherapy for metastatic lung cancer as oligo-recurrence: an analysis of 42 cases.

Takahashi W, Yamashita H, Niibe Y, Shiraishi K, Hayakawa K, Nakagawa K - Pulm Med (2012)

Bottom Line: The most commonly observed late effect was radiation pneumonitis.No other ≧ grade 3 acute and late adverse events occurred.Conclusions.

View Article: PubMed Central - PubMed

Affiliation: Department of Radiology, University of Tokyo Hospital, 7-3-1, Hongo, Bunkyo-ku, Tokyo 113-8655, Japan.

ABSTRACT
Purpose. To investigate the outcome and toxicity of stereotactic body radiotherapy (SBRT) in patients with oligo-recurrence cancer in the lung (ORCL). Methods and Materials. A retrospective review of 42 patients with ORCL who underwent SBRT in our two hospitals was conducted. We evaluated the outcome and adverse effects after SBRT for ORCL. Results. All patients finished their SBRT course without interruptions of toxicity reasons. The median follow-up period was 20 months (range, 1-90 months). The 2-year local control rate and overall survival were 87% (95% CI, 75-99%) and 65% (95% CI, 48-82%). As for prognostic factor, the OS of patients with a short disease-free interval (DFI) <31.9 months, between the initial therapy and SBRT for ORCL, was significantly worse than the OS of long DFI ≧31.9 months (P < 0.05). The most commonly observed late effect was radiation pneumonitis. One patient had grade 4 gastrointestinal toxicity (perforation of gastric tube). No other ≧ grade 3 acute and late adverse events occurred. There were no treatment-related deaths during this study. Conclusions. In patients with ORCL, radical treatment with SBRT is safe and provides a chance for long-term survival by offering favorable local control.

No MeSH data available.


Related in: MedlinePlus

Kaplan-Meier curves for overall survival in 42 patients with oligo-recurrence cancer in the lung, cancers from colorectal cancer and ones from other origins.
© Copyright Policy - open-access
Related In: Results  -  Collection


getmorefigures.php?uid=PMC3472526&req=5

fig3: Kaplan-Meier curves for overall survival in 42 patients with oligo-recurrence cancer in the lung, cancers from colorectal cancer and ones from other origins.

Mentions: In present study, seven patients with ORCL originated from CRC and 35 patients originated from other origins were treated by SBRT. The 1- and 2-year LCR in ORCL from CRC and in ORCL from other origins were 83% and 67%, 89% and 89%, respectively (Figure 2).The overall 1- and 2-year survival rates in ORCL from CRC and in ORCL from other origins were 85% and 85%, 82% and 63%, respectively (Figure 3). These results showed no significant difference in LCR (P = 0.31) and OS (P = 0.26).


Stereotactic body radiotherapy for metastatic lung cancer as oligo-recurrence: an analysis of 42 cases.

Takahashi W, Yamashita H, Niibe Y, Shiraishi K, Hayakawa K, Nakagawa K - Pulm Med (2012)

Kaplan-Meier curves for overall survival in 42 patients with oligo-recurrence cancer in the lung, cancers from colorectal cancer and ones from other origins.
© Copyright Policy - open-access
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC3472526&req=5

fig3: Kaplan-Meier curves for overall survival in 42 patients with oligo-recurrence cancer in the lung, cancers from colorectal cancer and ones from other origins.
Mentions: In present study, seven patients with ORCL originated from CRC and 35 patients originated from other origins were treated by SBRT. The 1- and 2-year LCR in ORCL from CRC and in ORCL from other origins were 83% and 67%, 89% and 89%, respectively (Figure 2).The overall 1- and 2-year survival rates in ORCL from CRC and in ORCL from other origins were 85% and 85%, 82% and 63%, respectively (Figure 3). These results showed no significant difference in LCR (P = 0.31) and OS (P = 0.26).

Bottom Line: The most commonly observed late effect was radiation pneumonitis.No other ≧ grade 3 acute and late adverse events occurred.Conclusions.

View Article: PubMed Central - PubMed

Affiliation: Department of Radiology, University of Tokyo Hospital, 7-3-1, Hongo, Bunkyo-ku, Tokyo 113-8655, Japan.

ABSTRACT
Purpose. To investigate the outcome and toxicity of stereotactic body radiotherapy (SBRT) in patients with oligo-recurrence cancer in the lung (ORCL). Methods and Materials. A retrospective review of 42 patients with ORCL who underwent SBRT in our two hospitals was conducted. We evaluated the outcome and adverse effects after SBRT for ORCL. Results. All patients finished their SBRT course without interruptions of toxicity reasons. The median follow-up period was 20 months (range, 1-90 months). The 2-year local control rate and overall survival were 87% (95% CI, 75-99%) and 65% (95% CI, 48-82%). As for prognostic factor, the OS of patients with a short disease-free interval (DFI) <31.9 months, between the initial therapy and SBRT for ORCL, was significantly worse than the OS of long DFI ≧31.9 months (P < 0.05). The most commonly observed late effect was radiation pneumonitis. One patient had grade 4 gastrointestinal toxicity (perforation of gastric tube). No other ≧ grade 3 acute and late adverse events occurred. There were no treatment-related deaths during this study. Conclusions. In patients with ORCL, radical treatment with SBRT is safe and provides a chance for long-term survival by offering favorable local control.

No MeSH data available.


Related in: MedlinePlus